about
Comparison of opioid-related deaths by work-related injuryPerformance of a Natural Language Processing (NLP) Tool to Extract Pulmonary Function Test (PFT) Reports from Structured and Semistructured Veteran Affairs (VA) DataModels solely using claims-based administrative data are poor predictors of rheumatoid arthritis disease activityMerging Veterans Affairs rheumatoid arthritis registry and pharmacy data to assess methotrexate adherence and disease activity in clinical practice.A Comparative Assessment of Observational Medical Outcomes Partnership and Mini-Sentinel Common Data Models and Analytics: Implications for Active Drug Safety Surveillance.Trends in Antibiotic Use and Nosocomial Pathogens in Hospitalized Veterans With Pneumonia at 128 Medical Centers, 2006-2010.Unintentional prescription opioid-related overdose deaths: description of decedents by next of kin or best contact, Utah, 2008-2009.Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis.The incident user design in comparative effectiveness research.A review of covariate selection for non-experimental comparative effectiveness research.Persistence and dose escalation of tumor necrosis factor inhibitors in US veterans with rheumatoid arthritis.Development and evaluation of a record linkage protocol for Utah's Controlled Substance Database.Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis.Variation in Empiric Coverage Versus Detection of Methicillin-Resistant Staphylococcus aureus and Pseudomonas aeruginosa in Hospitalizations for Community-Onset Pneumonia Across 128 US Veterans Affairs Medical Centers.Evaluation of the Case-Crossover (CCO) Study Design for Adverse Drug Event Detection.Body Mass Index, Weight Loss, and Cause-Specific Mortality in Rheumatoid Arthritis.Evidence generation from healthcare databases: recommendations for managing change.Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses.Identifying Axial Spondyloarthritis in Electronic Medical Records of US Veterans.The use of natural language processing on narrative medication schedules to compute average weekly dose.Persistence With Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans With Rheumatoid Arthritis.Associations of Circulating Cytokines and Chemokines With Cancer Mortality in Men With Rheumatoid Arthritis.Changes in Body Mass Related to the Initiation of Disease-Modifying Therapies in Rheumatoid Arthritis.Variation in Outpatient Antibiotic Prescribing for Acute Respiratory Infections in the Veteran Population: A Cross-sectional Study.Cause-Specific Mortality in Male US Veterans With Rheumatoid Arthritis.Mortality associated with lithium and valproate treatment of US Veterans Health Administration patients with mental disorders.Erratum to: A Comparative Assessment of Observational Medical Outcomes Partnership and Mini-Sentinel Common Data Models and Analytics: Implications for Active Drug Safety Surveillance.Propofol is associated with favorable outcomes compared with benzodiazepines in ventilated intensive care unit patients.Specialty of prescribers associated with prescription opioid fatalities in Utah, 2002-2010.Use of Disease-modifying Antirheumatic Drugs for Inflammatory Arthritis in US Veterans: Effect of Specialty Care and Geographic Distance.Mortality in American Veterans with the HLA-B27 gene.Impact of Obesity and Adiposity on Inflammatory Markers in Patients With Rheumatoid Arthritis.Errata to NLP study of infusion notes to identify outpatient infusions in the VA.The use of natural language processing of infusion notes to identify outpatient infusions.Initiation of Disease-Modifying Therapies in Rheumatoid Arthritis Is Associated With Changes in Blood Pressure.Adherence and virologic outcomes among treatment-naïve veteran patients with human immunodeficiency virus type 1 infection.Predicting poor adherence to antiretroviral therapy among treatment-naïve veterans infected with human immunodeficiency virus.Chronic lung disease in U.S. Veterans with rheumatoid arthritis and the impact on survivalBiologic and Glucocorticoid Use after Methotrexate Initiation in Patients with Rheumatoid ArthritisCohort identification of axial spondyloarthritis in a large healthcare dataset: current and future methods
P50
Q23918182-D03E75A0-1481-4764-93B9-9C7966FE7BF4Q31112246-EAD6198F-1650-40EC-AF9D-5DDE2B6ADA15Q33651231-47F5A0EF-4A34-4016-ACC0-392EB7B50F6AQ33873068-18019D16-18DB-4C49-96A6-8E417709EFE7Q35657554-0D0BDF5A-EFAE-46C6-9D48-DE138FDCB107Q36141276-60038E5A-9BCF-41A4-8CB9-838A2545A364Q36688679-2005D59F-3803-42AD-B73F-0DB0BF24E038Q37143744-B010F800-344E-4422-8BDA-C8C8C1C62277Q38048231-333FA5FF-8C3A-4B3B-91A4-A6155E46B8B3Q38134365-06FB026E-CE24-4256-8E23-1BC837DDAB08Q38395644-3AECA5E8-709A-474C-B28A-A87937556E2BQ38398103-660F25A3-4AF5-4A31-BCDC-D6DAF86BA810Q38580300-C4FAA1C0-24AD-4E0C-8124-EFFF505FB4FAQ38716765-6DCD70BD-0787-48BF-8A69-4337972B3349Q38802944-C59454B3-264A-48F1-8A0D-8B17023BD9C0Q38828456-4DCAE676-6BFE-491C-B763-65740736547FQ38835438-A7E74B43-D422-4CDE-A30D-19E43897C8F5Q38847344-4E677481-6315-42BD-BEFA-A49B59784F93Q39215614-1C113695-665D-4AD3-BD03-447F5DE43D0BQ39385266-D8F0A1B5-3581-4B28-AD60-8C7FC43EFEDFQ39702204-6D9EED41-1C00-442F-8E4D-143846774201Q39825022-1609F152-2E36-44C9-B037-610EBC6321C5Q39993473-2FDDCC2A-0C00-46F4-BC8B-CA85C26293B5Q40146565-C0D4562E-62AB-4D26-99C2-9D592B12B803Q40813488-C7F40C20-6516-4D8D-B8BD-B0F3C2B67A84Q41753288-9DC63742-6840-49E0-9481-8CBA6CE13295Q43576841-704CD8AD-122C-45A7-A897-D8AFDFDA4AE7Q43696320-D45006CB-0ECD-4D91-AD21-4D1E81C02930Q44160023-4A9720AE-BDF1-4CC1-83FD-58207233AA41Q45325753-F073BFFE-1F5A-4AC5-9482-AC1BA9F53195Q45328353-DE848251-6E3F-4E54-AB03-BBF30EA5BC65Q45940053-444F7485-0C9F-4EA9-841B-51CEEFE851CBQ48071255-D5CC83A7-76CC-4BD8-86DD-1FE0975D5B12Q48174753-86737DAA-43B5-4FB7-894B-E9C119266AA3Q52583114-8E30B7D4-CCBC-4255-800A-FF7557345C88Q52685421-AD01F629-32D7-43A4-A118-175F28AE1DD0Q54983515-DEF4CFA8-00FD-4BA7-B001-E971B47F4062Q57045253-34D248B3-A426-44E6-AF55-06332D4F0E63Q57058395-4E1372CE-16F7-47EA-9874-43AD7A1C74B5Q57160479-92E620D1-B0B0-46F4-A2A8-DB30E151A57F
P50
description
investigador
@es
researcher
@en
name
Brian C Sauer
@en
type
label
Brian C Sauer
@en
prefLabel
Brian C Sauer
@en
P31
P496
0000-0002-3546-3051